Search

Search Results

• 

  Three-dimensional morphological condylar and mandibular changes in a patient with juvenile idiopathic arthritis: interdisciplinary treatment

  G. Farronato, C. Bellintani, U. Garagiola, P. Cressoni, P. Sarzi Puttini, F. Atzeni, M. Cazzola

  254-257

  06-11-2014

  https://doi.org/10.4081/reumatismo.2014.725

  2658

  PDF: 1381
• 

  Aseptic HLA B27-positive spondylodiscitis: decreased 18F-FDG uptake after etanercept treatment

  M. Benucci, A. Damiani, A. Arena, M. Infantino, M. Manfredi, F. Li Gobbi

  163-165

  16-12-2016

  https://doi.org/10.4081/reumatismo.2016.911

  3256

  PDF: 837
• 

  Intra-articular therapy with tumor necrosis factor-α antagonists: an update

  S. Bello, C. Bonali, L. Serafino, C. Rotondo, N. Terlizzi, G. Lapadula

  257-263

  14-03-2014

  https://doi.org/10.4081/reumatismo.2013.721

  2720

  PDF: 1293
• 

  Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs

  F.M. Perrotta, O. Addimanda, R. Ramonda, S. D’Angelo, E. Lubrano, A. Marchesoni, I. Olivieri, L. Punzi, C. Salvarani, A. Spadaro

  208-214

  06-11-2014

  https://doi.org/10.4081/reumatismo.2014.756

  2807

  PDF: 1576

• Ultrasonographic assessment of the response to Etanercept treatment in patients with rheumatoid arthritis

  A. Iagnocco, C. Perella, F. Ceccarelli, E. Tripodo, C. Alessandri, L. Magrini, G. Valesini

  233-238

  https://doi.org/10.4081/reumatismo.2006.233

  1086

  PDF: 1037

• PO:10:155 | Etanercept-induced lupus in a patient with rheumatoid arthritis: diagnostic challenges and multidisciplinary therapeutic approach Camilla Riboldi^1|2, Claudia Iannone^1|2, Maria Gerosa^1|2, Roberto Felice Caporali^1|2 | ¹ASST G. Pini-CTO, U.O.C. di Clinica Reumatologica, Milano; ²Dipartimento di Scienze Cliniche e di Comunità, Università degli Studi di Milano, Italy

  Società Italiana di Reumatologia

  26-11-2025

  https://doi.org/10.4081/reumatismo.2025.2149

  83

• Intra-articular etanercept treatment for severe diffuse pigmented villonodular knee synovitis

  U. Fiocco, P. Sfriso, F. Oliviero, F. Sovran, E. Scagliori, E. Pagnin, M. Vezzù, L. Cozzi, C. Botsios, R. Nardacchione, A. Di Maggio, L. Rubaltelli, C. Giacometti, F. Calabrese, S. Todesco

  268-274

  https://doi.org/10.4081/reumatismo.2006.268

  1679

  PDF: 2739

• The treatment of recurrent uveitis with TNFα inhibitors

  P.C.F. Falappone, F. Iannone, C. Scioscia, V. Grattagliano, M. Covelli, G. Lapadula

  185-189

  https://doi.org/10.4081/reumatismo.2004.185

  1840

  PDF: 2458
• 

  Psoriatic arthritis: treatment strategies using biologic agents

  S. D'Angelo, C. Palazzi, I. Olivieri

  113-121

  05-06-2012

  https://doi.org/10.4081/reumatismo.2012.113

  1367

  PDF: 1198

• Biologic therapy with anti-TNFa in spondyloarthritides and other autoimmune diseases

  G. Lapadula

  22-29

  https://doi.org/10.4081/reumatismo.2005.4s.22

  864

  PDF: 1128

• Side effects of anti-TNFa therapy in juvenile idiopathic arthritis

  Irene Pontikaki, Valeria Gerloni, Maurizio Gattinara, Alfredomaria Lurati, Alessandra Salmaso, Gabriele De Marco, Barbara Teruzzi, Elisabetta Valcamonica, Flavio Fantini

  31-38

  https://doi.org/10.4081/reumatismo.2006.31

  1869

  PDF: 2593

• Response to anti-TNF-α treatment for secondary renal amyloidosis in a patient with ankylosing spondylitis

  S. Bellissimo, M.G. Ferrucci, A. Gallo, S. Stisi

  240-243

  https://doi.org/10.4081/reumatismo.2007.240

  1085

  PDF: 1215

• Anti-TNFa treatment in patients with rheumatoid arthritis and anti-Ro/SSA antibodies

  I. Cavazzana, F. Franceschini, E. Danieli, M. Frassi, M. Vianelli, R. Gorla, P. Airò, R. Cattaneo

  267-272

  https://doi.org/10.4081/reumatismo.2005.267

  1143

  PDF: 1793
• 

  Anti-tumor necrosis factor α: originators versus biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies

  C. Gioia, A. Picchianti Diamanti, R. Perricone, M.S. Chimenti, A. Afeltra, L. Navarini, A. Migliore, U. Massafra, V. Bruzzese, P. Scolieri, C. Meschini, M. Paroli, R. Caccavale, P. Scapato, R. Scrivo, F. Conti, B. Laganà, M. Di Franco

  19-12-2023

  https://doi.org/10.4081/reumatismo.2023.1602

  2037

  PDF: 504
• 

  Etanercept biosimilar associated with Guillain-Barré syndrome: insights from a case

  V. Shobha, A.M. Desai, T. Matthew

  99-102

  09-07-2019

  https://doi.org/10.4081/reumatismo.2019.1115

  1423

  PDF: 904
• 

  A short history of anti-rheumatic therapy - VII. Biological agents

  G. Pasero, P. Marson, B. Gatto

  185-194

  09-11-2011

  https://doi.org/10.4081/reumatismo.2011.185

  1618

  PDF: 1281
• 

  Jaccoud’s arthropathy, an unusual manifestation of idiopathic retroperitoneal fibrosis: rapid improvement of symptoms after tocilizumab treatment

  M. Benucci, A. Damiani, F. Li Gobbi, V. Grossi, M. Infantino, A. Arena, M. Manfredi

  88-91

  03-08-2017

  https://doi.org/10.4081/reumatismo.2017.968

  2235

  PDF: 1065
• 

  GISEA: an Italian biological agents registry in rheumatology

  G. Lapadula, G. Ferraccioli, C. Ferri, L. Punzi, F. Trotta

  155-164

  09-11-2011

  https://doi.org/10.4081/reumatismo.2011.155

  2525

  PDF: 1649

• Safety of anti-TNFa biological drugs

  F. Trotta, G. Valentini

  34-39

  https://doi.org/10.4081/reumatismo.2005.4s.34

  1237

  PDF: 1288

• Correlation between radiographic, echographic and MRI changes and rheumatoid arthritis progression

  M.A. Cimmino, M. Parodi, E. Silvestri, G. Garlaschi

  28-40

  https://doi.org/10.4081/reumatismo.2004.1s.28

  1079

  PDF: 2983

• Approved indications and other possible utilizations of anti-TNFa biologic drugs

  W. Grassi, C. Montecucco

  30-33

  https://doi.org/10.4081/reumatismo.2005.4s.30

  1227

  PDF: 912

• Analysis of the kinetic of expression of tristetraprolin and HuR by rheumatoid arthritis patients pheripheral blood mononuclear cells stimulated with lipopolysaccharide

  M. Fabris, B. Tolusso, E. Gremese, P. Tomietto, G. Ferraccioli

  94-103

  https://doi.org/10.4081/reumatismo.2004.94

  1433

  PDF: 969

• Biologic therapy with anti-TNFa in rheumathoid atrhritis

  G. Ferraccioli

  17-21

  https://doi.org/10.4081/reumatismo.2005.4s.17

  815

  PDF: 723

• Are there any positive effects of TNF-alpha blockers on bone metabolism?

  B. Seriolo, S. Paolino, A. Sulli, M. Cutolo

  199-205

  https://doi.org/10.4081/reumatismo.2006.199

  1342

  PDF: 1217

• Infections in patients with rheumatoid arthritis receiving anti-cytokine therapy: biological mechanisms and clinical aspects

  C. Botsios, P. Ostuni, P. Sfriso, A. Furlan, U. Fiocco, D. Sgarabotto, S. Todesco

  224-235

  https://doi.org/10.4081/reumatismo.2003.224

  1216

  PDF: 2649

• Differences in pharmacology of tumor necrosis factor (TNF) antagonists

  U. Fiocco, S. Bombardieri

  8-16

  https://doi.org/10.4081/reumatismo.2005.4s.8

  1247

  PDF: 1797

• Kidney involvement in rheumatoid arthritis

  A. Icardi, P. Araghi, M. Ciabattoni, U. Romano, P. Lazzarini, G. Bianchi

  76-85

  https://doi.org/10.4081/reumatismo.2003.76

  5739

  PDF: 7713

• Switching between TNFα antagonists in rheumatoid arthritis: personal experience and review of the literature

  R. Scrivo, F. Conti, F.R. Spinelli, S. Truglia, L. Magrini, M. Di Franco, F. Ceccarelli, G. Valesini

  107-117

  https://doi.org/10.4081/reumatismo.2009.107

  1988

  PDF: 1212

• Effects of TNF antagonists on immune and neuroendocrine system

  G. Valesini, M. Cutolo

  3-7

  https://doi.org/10.4081/reumatismo.2005.4s.3

  1303

  PDF: 822

• A comparison between the Simplified Disease Activity Index (SDAI) and the Disease Activity Score (DAS28) as measure of response to treatment in patients undergoing different therapeutic regimens

  Giovanna Cuomo, Gabriella Molinaro, Giovanni La Montagna, Sergio Migliaresi, Gabriele Valentini

  22-25

  https://doi.org/10.4081/reumatismo.2006.22

  1616

  PDF: 2058

• PO:02:024 | Development of anti-drug antibodies in patients with peripheral and/or axial spondyloarthritis treated with infliximab or adalimumab: a monocentric cross-sectional study Gabriele Amati¹, Gilda Sandri^1|2, Alessandra Melegari³, Benedetta Bongiovanni^1|2, Giovanni Ciancio², Martina Orlandi^1|2, Ottavio Secchi¹, Dilia Giuggioli^1|2 | ¹Struttura complessa di Reumatologia, Azienda Ospedaliero-Universitaria Policlinico di Modena; ²Cattedra di Reumatologia, Università degli studi di Modena e Reggio Emilia; ³Dipartimento di medicina di laboratorio, Ospedale di Baggiovara, AUSL di Modena, Italy

  Società Italiana di Reumatologia

  26-11-2025

  https://doi.org/10.4081/reumatismo.2025.2126

  88
• 

  Inflammatory back pain as an unusual manifestation of Takayasu arteritis: a case report

  Faiq Gorial, Nabaa Awadh, Ali Al-Shakarchi, Ghaith Al-Gburi

  30-10-2024

  https://doi.org/10.4081/reumatismo.2024.1678

  2007

  PDF: 364

• Recurrent new-onset uveitis in a patient with rheumatoid arthritis during anti-TNFα treatment

  M. Di Gangi, R. Foti, R. Leonardi, C. Leonetti, P. Castellino

  169-172

  https://doi.org/10.4081/reumatismo.2007.169

  1109

  PDF: 1036